BioCentury
ARTICLE | Company News

Dr. Reddy's, Galena Biopharma deal

January 20, 2014 8:00 AM UTC

Galena granted Dr. Reddy's exclusive rights to develop and commercialize NeuVax nelipepimut-S to treat breast and gastric cancer in India. Dr. Reddy's is responsible for conducting a Phase II trial in gastric cancer, which is slated to start this year, and for regulatory submissions in India. Galena received an upfront payment and is eligible for milestones, plus double-digit royalties. Galena declined to disclose financial details, and Dr. Reddy's could not be reached.

NeuVax is in the Phase III PRESENT trial to prevent recurrence of early stage, node-positive breast cancer with low to intermediate HER2 expression. The trial has a SPA from FDA...